Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each p...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_78803 | ||
| 005 | 20220224 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220224s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-2686-7 | ||
| 020 | |a 9783036526867 | ||
| 020 | |a 9783036526874 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2686-7 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a KNDP |2 bicssc | |
| 100 | 1 | |a Kayser, Veysel |4 edt | |
| 700 | 1 | |a Kayser, Veysel |4 oth | |
| 245 | 1 | 0 | |a Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (298 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmaceutical industries |2 bicssc | |
| 653 | |a monoclonal antibody | ||
| 653 | |a NSCLC | ||
| 653 | |a immunotherapy | ||
| 653 | |a ELISA | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a pharmacogenetics | ||
| 653 | |a anti-PD-1 monoclonal antibodies | ||
| 653 | |a anti-acetylcholine receptor (AChR) antibody | ||
| 653 | |a B cell | ||
| 653 | |a immune checkpoint blockade | ||
| 653 | |a immune-related adverse events (irAEs) | ||
| 653 | |a myasthenia gravis (MG) | ||
| 653 | |a non-small-cell lung cancer (NSCLC) | ||
| 653 | |a nivolumab | ||
| 653 | |a programmed cell death ligand 1 (PD-L1) | ||
| 653 | |a T cell | ||
| 653 | |a tetraspanins | ||
| 653 | |a cancer | ||
| 653 | |a Tspan8 | ||
| 653 | |a radioimmunotherapy | ||
| 653 | |a immune-checkpoint inhibitors | ||
| 653 | |a LDH | ||
| 653 | |a biomarkers | ||
| 653 | |a Ang-2 | ||
| 653 | |a antiangiogenic therapy | ||
| 653 | |a in vivo imaging | ||
| 653 | |a radio- and chemotherapy | ||
| 653 | |a VEGF-A | ||
| 653 | |a cancer therapy | ||
| 653 | |a neovascularization | ||
| 653 | |a angiogenesis | ||
| 653 | |a tumor microenvironment | ||
| 653 | |a colorectal cancer | ||
| 653 | |a antibody | ||
| 653 | |a NK cells | ||
| 653 | |a ADCC | ||
| 653 | |a CD133 | ||
| 653 | |a prominin-1 | ||
| 653 | |a gold nanoparticles | ||
| 653 | |a antibody-drug conjugates | ||
| 653 | |a cell penetrating peptide | ||
| 653 | |a HIV-1 TAT | ||
| 653 | |a active-targeting | ||
| 653 | |a targeted delivery | ||
| 653 | |a trastuzumab | ||
| 653 | |a MMAE | ||
| 653 | |a valine-citrulline | ||
| 653 | |a affibody | ||
| 653 | |a drug conjugates | ||
| 653 | |a hepatic uptake | ||
| 653 | |a DM1 | ||
| 653 | |a dermatooncology | ||
| 653 | |a immune checkpoints | ||
| 653 | |a monoclonal antibodies | ||
| 653 | |a passive immunotherapy | ||
| 653 | |a canine B-cell lymphoma | ||
| 653 | |a DLA-DR | ||
| 653 | |a HLA-DR | ||
| 653 | |a antibody-drug conjugate | ||
| 653 | |a ADC | ||
| 653 | |a methotrexate | ||
| 653 | |a tumor immunity | ||
| 653 | |a combination therapy | ||
| 653 | |a multiple myeloma (MM) | ||
| 653 | |a monoclonal antibodies (mAbs) | ||
| 653 | |a antibody products | ||
| 653 | |a B cell maturation antigens (BCMAs) | ||
| 653 | |a bispecific T cell engagers (BiTEs®) | ||
| 653 | |a checkpoint inhibitors 1 | ||
| 653 | |a protein structure 2 | ||
| 653 | |a pharmacokinetics 3 | ||
| 653 | |a drug optimization 4 | ||
| 653 | |a HER2-positive breast cancer | ||
| 653 | |a metastatic disease | ||
| 653 | |a neoadjuvant and adjuvant therapy | ||
| 653 | |a targeted therapy | ||
| 653 | |a acute myeloid leukemia | ||
| 653 | |a CD123 | ||
| 653 | |a IL3RA | ||
| 653 | |a kinesin spindle protein inhibitor | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/4898 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/78803 |7 0 |z DOAB: description of the publication |